The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Open accessAbstract
BACKGROUND: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. RESULTS: Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68%, as compared with 57% in the control group; at 2 years, the rates were 41% and 27%, respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95% confidence interval, 0.57 to 0.85; P<0.001). The overall response rate in the elotuzumab group was 79%, versus 66% in the control group (P<0.001). Common grade 3 or 4 adverse events in the two groups were lymphocytopenia, neutropenia, fatigue, and pneumonia. Infusion reactions occurred in 33 patients (10%) in the elotuzumab group and were grade 1 or 2 in 29 patients. CONCLUSIONS: Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-2 ClinicalTrials.gov number, NCT01239797.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike daratumumab, elotuzumab does not have single-agent activity but shows synergistic activity when combined with Rd (Table 8).84”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [84]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Elotuzumab targets SLAMF7; daratumumab and isatuximab target CD38 respectively.84–87”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [84]
The cited source says what the claim attributes to it.
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [30]
In the citing paper
“Elotuzumab has been proposed to function at least partially through upregulation of IL-2 production by T cells and stimulation of natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC)68–70.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationCS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Hsi, E. D., Steinle, R., Balasa, B., Szmania, S. M., Draksharapu, A., Shum, B. P., Huseni, M. A., Powers, D., Nanisetti, A., Zhang, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4246 · Cited by 558
SLAM Family Receptors and SAP Adaptors in Immunity
Cannons, J. L., Tangye, S. G., & Schwartzberg, P. L. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101302 · Cited by 502
Tai, Y., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2007) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 472
Self-citationVoskens, C., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 465
Dimopoulos, M. A., Chen, C. L., Spencer, A. G., Niesvizky, R., Attal, M., Stadtmauer, E. A., Petrucci, M. T., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2009) · Leukemia · doi:10.1038/leu.2009.147 · Cited by 366
Self-citationCollins, S. M., Bakan, C. E., Swartzel, G. D., Hofmeister, C. C., Efebera, Y. A., Kwon, H., Starling, G. C., Ciarlariello, D., Bhaskar, S., Briercheck, E. L., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1493-8 · Cited by 296
Richardson, P. G. G., Baz, R., Wang, M. L., Jakubowiak, A. J., Laubach, J. P., Harvey, R. D., Talpaz, M., Berg, D. T., Liu, G., Jiang, Y., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548826 · Cited by 202
Self-citationPérez‐Quintero, L., Roncagalli, R., Guo, H., Latour, S., Davidson, D., & Veillette, A. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20132038 · Cited by 93
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,000
Hasegawa, K., Ikeda, S., Yaga, M., Watanabe, K., Urakawa, R., Iehara, A., Iwai, M., Hashiguchi, S., Morimoto, S., Fujiki, F., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.aax7706 · Cited by 29
How I treat triple‐class refractory multiple myeloma
Costa, L. J., Hungria, V., Mohty, M., & Mateos, M. (2022) · British Journal of Haematology · doi:10.1111/bjh.18185 · Cited by 29
Self-citationA review of the venous thrombotic issues associated with multiple myeloma
Fotiou, D., Gerotziafas, G., Kastritis, E., Dimopoulos, M. A., & Terpos, E. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1194750 · Cited by 29
Self-citationRecent advances in multiple myeloma: a Korean perspective
Hong, J., & Lee, J. H. (2016) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.408 · Cited by 29
Steroid-Associated Side Effects: A Symptom Management Update on Multiple Myeloma Treatment
King, T., & Faiman, B. M. (2017) · Clinical journal of oncology nursing · doi:10.1188/17.cjon.240-249 · Cited by 29
SLE-Associated Defects Promote Altered T Cell Function
Crispín, J. C., Hedrich, C. M., Suárez‐Fueyo, A., Comte, D., & Tsokos, G. C. (2017) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2018025213 · Cited by 29
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
de Arriba de la Fuente, F., Montes Gaisán, C., & de la Rubia Comos, J. (2022) · Cancers · doi:10.3390/cancers15010155 · Cited by 28
Signaling lymphocytic activation molecules Slam and cancers: friends or foes?
Fouquet, G., Marcq, I., Debuysscher, V., Bayry, J., Singh, A. R., Bengrine, A., Nguyen-Khac, É., Naassïla, M., & Bouhlal, H. (2018) · Oncotarget · doi:10.18632/oncotarget.24575 · Cited by 28
Fernando, R. C., Mazzotti, D. R., de Azevedo, H. F. Z., Sandes, A. F., Rizzatti, E. G., de Oliveira, M. B., Alves, V. L. F., Eugênio, A. I. P., de Carvalho, F., Dalboni, M. A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-38314-8 · Cited by 29
Ochoa, M. C., Pérez-Ruiz, E., Minute, L., Oñate, C., Pérez, G., Rodríguez, I., Zabaleta, A., Alignani, D., Fernández-Sendin, M., López, A., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1599636 · Cited by 28
Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets
Nishida, H., & Yamada, T. (2019) · Journal of Oncology · doi:10.1155/2019/6084012 · Cited by 28
Immunotherapy for the treatment of multiple myeloma
Jung, S., Lee, H., Vo, M.-C., Kim, H., & Lee, J. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.011 · Cited by 29
Triplet vs. doublet drug regimens for managing multiple myeloma
Offidani, M., Corvatta, L., & Gentili, S. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1418856 · Cited by 28
Leleu, X. P., Gay, F., Flament, A., Allcott, K., & Delforge, M. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3191-7 · Cited by 28
Dimopoulos, M. A., Kaufman, J. L., White, D. J., Cook, G., Rizzo, M., Xu, Y., Fahrbach, K. R., Gaudig, M., Slavcev, M., Dearden, L., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.12.011 · Cited by 28
Self-citationPopková, T., Hájek, R., & Jelı́nek, T. (2020) · British Journal of Haematology · doi:10.1111/bjh.16436 · Cited by 28
Sequencing multiple myeloma therapies with and after antibody therapies
van de Donk, N. W. C. J. (2020) · Hematology · doi:10.1182/hematology.2020000109 · Cited by 27
Hotspots and trends in multiple myeloma bone diseases: A bibliometric visualization analysis
Hou, Z., Jiang, P., Su, S., & Zhou, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1003228 · Cited by 27
Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential
Lica, J. J., Pradhan, B., Safi, K., Jakóbkiewicz‐Banecka, J., & Hellmann, A. (2024) · Molecules · doi:10.3390/molecules29174280 · Cited by 29
CARs and other T cell therapies for MM: The clinical experience
Danhof, S., Hudecek, M., & Smith, E. L. (2018) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2018.03.002 · Cited by 27
Advancements in Nanomedicine for Multiple Myeloma
Detappe, A., Bustoros, M. W., Mouhieddine, T. H., & Ghoroghchian, P. P. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.04.005 · Cited by 27
Novel targets for the treatment of relapsing multiple myeloma
Giuliani, N., Accardi, F., Marchica, V., Palma, B. D., Storti, P., Toscani, D., Vicario, E., & Malavasi, F. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1624158 · Cited by 28
Use of daratumumab in high risk multiple myeloma: A meta‐analysis
Premkumar, V. J., Pan, S. M., Lentzsch, S., & Bhutani, D. (2020) · eJHaem · doi:10.1002/jha2.47 · Cited by 27
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment
Liu, J., Hideshima, T., Xing, L., Wang, S., Zhou, W., Samur, M., Sewastianik, T., Ogiya, D., An, G., Gao, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg2697 · Cited by 27
Self-citationOn the road to eliminating long‐lived plasma cells—“are we there yet?”
Markmann, C., & Bhoj, V. G. (2021) · Immunological Reviews · doi:10.1111/imr.13015 · Cited by 27
Mané-Damas, M., Molenaar, P. C., Ulrichts, P., Marcuse, F. D., Baets, M. H. D., Martínez‐Martínez, P., & Losen, M. H. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103104 · Cited by 27
Gaballa, S. R., Saliba, R. M., Srour, S. A., Lu, G. G., Brammer, J. E., Shah, N. D., Bashir, Q., Patel, K. K., Bock, F. M., Parmar, S., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24487 · Cited by 27
Self-citationRosenzweig, M. A., Urak, R. Z., Walter, M., Lim, L., Sanchez, J. F., Krishnan, A. Y., Forman, S. J., & Wang, X. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.03.077 · Cited by 27
Novel Agents in Multiple Myeloma
Szalat, R. E., & Munshi, N. C. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000355 · Cited by 27
Conticello, C., Romano, A., Fabro, V. D., Martino, E. A., Calafiore, V., Sapienza, G., Leotta, V., Parisi, M. S., Markovic, U., Garibaldi, B., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060877 · Cited by 27
Atkin, C., Reddy‐Kolanu, V., Drayson, M. T., Sapey, E., & Richter, A. G. (2020) · British Journal of Haematology · doi:10.1111/bjh.16487 · Cited by 27
Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study
Rosenzweig, M. A., Palmer, J. M., Tsai, N., Synold, T. W., Wu, X., Tao, S., HAMMOND, S. N., Buettner, R., Duarte, L., Htut, M., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1742900 · Cited by 27
Monoclonal Antibodies in Multiple Myeloma Come of Age
Raje, N. S., & Longo, D. L. (2015) · New England Journal of Medicine · doi:10.1056/nejme1509419 · Cited by 27
Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review
Sparano, F., Cavo, M., Niscola, P., Caravita, T., & Efficace, F. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4137-x · Cited by 26
Herpesvirus Infections Potentiated by Biologics
Ho, D. Y., Enriquez, K. T., & Multani, A. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.02.006 · Cited by 26
Immunotherapeutic and Targeted Approaches in Multiple Myeloma
Nadeem, O., Tai, Y., & Anderson, K. C. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s240886 · Cited by 26
Self-citationMonoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
D’Agostino, M., Innorcia, S., Boccadoro, M., & Bringhen, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218192 · Cited by 28
Afifi, S., Michael, A., & Lesokhin, A. M. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016642786 · Cited by 26
Mechanisms of Resistance in Multiple Myeloma
Papadas, A., & Asimakopoulos, F. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_10 · Cited by 26
Managing multiple myeloma in elderly patients
Diamond, E., Lahoud, O. B., & Landau, H. J. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1365859 · Cited by 26
Avet‐Loiseau, H., & Facon, T. T. F. (2018) · Leukemia · doi:10.1038/s41375-018-0098-9 · Cited by 26
Mikhael, J. R., Manola, J. B., Dueck, A. C., Hayman, S. R., Oettel, K. R., Kanate, A. S., Lonial, S., & Rajkumar, S. V. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0110-7 · Cited by 26
Self-citationIxazomib: a novel drug for multiple myeloma
Zanwar, S., Abeykoon, J. P., & Kapoor, P. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1518129 · Cited by 27
Sweiss, K. I., Wirth, S. M., Sharp, L. K., Park, I., Sweiss, H., Rondelli, D., & Patel, P. R. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00085 · Cited by 26
Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism
Marofi, F., Tahmasebi, S., Rahman, H. S., Kaigorodov, D., Markov, A. A., Yumashev, A. V., Shomali, N., Chartrand, M. S., Pathak, Y. V., Mohammed, R. N., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02283-z · Cited by 28
Robinson, R. M., Reyes, L., Duncan, R. M., Bian, H., Strobel, E. D., Hyman, S. L., Reitz, A. B., & Dolloff, N. G. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111906 · Cited by 25
Immunotherapy for Multiple Myeloma
Tamura, H., Ishibashi, M., Sunakawa, M., & Inokuchi, K. (2019) · Cancers · doi:10.3390/cancers11122009 · Cited by 25
Demel, I., Bago, J., Hájek, R., & Jelı́nek, T. (2020) · British Journal of Haematology · doi:10.1111/bjh.17235 · Cited by 25
Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma
Ishibashi, M., Morita, R., & Tamura, H. (2021) · Cancers · doi:10.3390/cancers13020279 · Cited by 25
Clonal Evolution of Multiple Myeloma—Clinical and Diagnostic Implications
Salomon‐Perzyński, A., Jamroziak, K., & Głodkowska‐Mrówka, E. (2021) · Diagnostics · doi:10.3390/diagnostics11091534 · Cited by 26
Current Novel Targeted Therapeutic Strategies in Multiple Myeloma
Lin, C. (.-T., Tariq, M., Ullah, F., Sannareddy, A., Khalid, F., Abbas, H., Bader, A., Samaras, C., Valent, J., Khouri, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116192 · Cited by 25
Development of Novel Immunotherapies for Multiple Myeloma
Al-Hujaily, E. M., Oldham, R. A. A., Hari, P., & Medin, J. A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091506 · Cited by 25
Miguel, J. F. S., Einsele, H., & Moreau, P. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0413-7 · Cited by 25
Self-citationEnd points and statistical considerations in immuno-oncology trials: impact on multiple myeloma
Hoering, A., Durie, B. G. M., Wang, H., & Crowley, J. J. (2017) · Future Oncology · doi:10.2217/fon-2016-0504 · Cited by 25
Tan, D. C. L., Lee, J. H., Chen, W.-M., Shimizu, K., Hou, J., Suzuki, K., Nawarawong, W., Huang, S., Chim, C. S., Kım, K., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1427858 · Cited by 25
Oostvogels, R., Jak, M., Raymakers, R. A. P., Mous, R., & Minnema, M. C. (2018) · British Journal of Haematology · doi:10.1111/bjh.15504 · Cited by 25
Hirano, M., Imai, Y., Kaito, Y., Murayama, T., Sato, K., Ishida, T., Yamamoto, J., Ito, T., Futami, M., Ri, M., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01909-7 · Cited by 25
Richardson, P. G. G., Harvey, R. D., Laubach, J. P., Moreau, P., Lonial, S., & Miguel, J. F. S. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1096773 · Cited by 24
Self-citationThe prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma
Rotolo, A., Caputo, V. S., & Karadimitris, A. (2016) · British Journal of Haematology · doi:10.1111/bjh.13976 · Cited by 25
Hari, P., Mateos, M., Abonour, R., Knop, S. T., Bensinger, W., Ludwig, H., Song, K., Hájek, R., Moreau, P., Siegel, D. S. D., et al. (2017) · Leukemia · doi:10.1038/leu.2017.122 · Cited by 24
Self-citationProgression with clinical features is associated with worse subsequent survival in multiple myeloma
Chakraborty, R., Liu, H. D., Rybicki, L. A., Tomer, J., Khouri, J., Dean, R. M., Faiman, B. M., Kalaycio, M. E., Samaras, C. J., Majhail, N. S., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25415 · Cited by 24
Zhu, S., Chen, Y., Lao, J., Wu, C., Zhan, X., Wu, Y., Shang, Y., Zou, Z., Zhou, J., Ji, X., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa445 · Cited by 24
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma
Romano, A., Storti, P., Marchica, V., Scandura, G., Notarfranchi, L., Craviotto, L., Raimondo, F. D., & Giuliani, N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684561 · Cited by 24
An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy
Quazi, S. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.12.003 · Cited by 24
Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab
Einsele, H., & Schreder, M. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716657993 · Cited by 24
Self-citationManaging renal complications in multiple myeloma
Fotiou, D., Dimopoulos, M. A., & Kastritis, E. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1210003 · Cited by 24
Self-citationRecent advances in understanding multiple myeloma
Dhakal, B., Girnius, S. K., & Hari, P. (2016) · F1000Research · doi:10.12688/f1000research.8777.1 · Cited by 25
Novel anti-myeloma immunotherapies targeting the SLAM family of receptors
Radhakrishnan, S. V., Bhardwaj, N., Luetkens, T., & Atanackovic, D. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1308618 · Cited by 24
Jakubowiak, A. J., Houisse, I., Majer, I. M., Benedict, Á., Campioni, M., Panjabi, S. S., & Ailawadhi, S. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1391088 · Cited by 24
Waldschmidt, J. M., Anand, P., Knoechel, B., & Lohr, J. G. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.02.010 · Cited by 25
Iqbal, S. M., Stecklein, K., Sarow, J. L., Krabak, M. J., Hillengaß, J., & McCarthy, P. L. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.08.021 · Cited by 24
Mian, H. S., Mian, O., Rochwerg, B. N., Foley, R., & Wildes, T. M. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.05.014 · Cited by 24
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials
Martino, M. V., Rossi, M., Ferreri, A., Loteta, B., Morabito, A., Moscato, T., Console, G., Innao, V., Naso, V., Provenzano, P. F., et al. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1634541 · Cited by 24
Current Development of Monoclonal Antibodies in Cancer Therapy
Parakh, S., King, D., Gan, H. K., & Scott, A. M. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_1 · Cited by 25
Rosenberg, A. S., Brunson, A. M., Tuscano, J. M., Jonas, B. A., Hoeg, R. T., Wun, T., & Keegan, T. H. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-020-00400-4 · Cited by 24
Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
Ackley, J. C., Ochoa, M. A., Ghoshal, D., Roy, K., Lonial, S., & Boise, L. (2021) · Cancers · doi:10.3390/cancers13194787 · Cited by 25
Self-citationHosny, M., Verkleij, C. P. M., van der Schans, J., Frerichs, K. A., Mutis, T., Zweegman, S., & van de Donk, N. W. C. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194593 · Cited by 24
Luo, X., Du, X., Li, J.-L., Liu, X., & Meng, X. (2018) · Cancer Management and Research · doi:10.2147/cmar.s166640 · Cited by 23
Multiple Myeloma: What Do We Do About Immunodeficiency?
Li, L., & Wang, L. (2019) · Journal of Cancer · doi:10.7150/jca.29993 · Cited by 23
Gomez-Arteaga, A., Mark, T. M., Guarneri, D., Christos, P. J., Gergis, U. S., Greenberg, J., Hsu, J., Mayer, S. A., Niesvizky, R., Pearse, R. N., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0587-0 · Cited by 23
Melflufen for relapsed and refractory multiple myeloma
Oriol, A., Larocca, A., Leleu, X. P., Hájek, R., Hassoun, H., Rodríguez‐Otero, P., Paner, A., Schjesvold, F. H., Gullbo, J., & Richardson, P. G. G. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1808884 · Cited by 24
Self-citationRapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review
Nishida, H. (2021) · Cancers · doi:10.3390/cancers13112712 · Cited by 23
Özlü, C. (2021) · JOURNAL OF BIOTECHNOLOGY AND STRATEGIC HEALTH RESEARCH · doi:10.34084/bshr.948974 · Cited by 23
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
Abramson, H. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115674 · Cited by 23
Therapeutic progress in relapsed/refractory multiple myeloma
Chen, Q., Zhang, M., Zheng, S., Tong, Y., & Tan, Y. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05730-y · Cited by 26
Rosenberg, A. S., Pariser, A., Diamond, B., Yao, L. P., Turka, L. A., Lacaná, E., & Kishnani, P. S. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.02.009 · Cited by 23
Raje, N. S., Faber, E. A., Richardson, P. G. G., Schiller, G. J., Hohl, R. J., Cohen, A. D., Forero, A., Carpenter, S. P., Nguyen, T. S., Conti, I., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0201 · Cited by 24
Self-citationKinase inhibitors as potential agents in the treatment of multiple myeloma
Abramson, H. N. (2016) · Oncotarget · doi:10.18632/oncotarget.10745 · Cited by 23
Cohen, Y. C., Magen, H., Lavi, N., Gatt, M. E., Chubar, E., Horowitz, N. A., Kreiniz, N., Tadmor, T., Trestman, S., Vitkon, R., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-03985-9 · Cited by 23
Self-citationTurner, J. G., Cui, Y., Bauer, A. A., Dawson, J. L., Gomez, J. A., Kim, J., Cubitt, C. L., Nishihori, T., Dalton, W. S., & Sullivan, D. M. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-0677 · Cited by 23
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy
Zamagni, E., Tacchetti, P., Pantani, L., & Cavo, M. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1456331 · Cited by 22
The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma
Feinberg, D. M., Paul, B. A., & Kang, Y. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.103964 · Cited by 23
Dhakal, B., D’Souza, A., Martens, M. J., Kapke, J. T., Harrington, A. M., Pasquini, M. C., Saber, W., Drobyski, W. R., Zhang, M. J., Hamadani, M., et al. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.03.001 · Cited by 22
Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials
Boudreault, J., Touzeau, C., & Moreau, P. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1285694 · Cited by 22
Self-citationCurrent Review on High-Risk Multiple Myeloma
Chan, H. S. H., Chen, C. I., & Reece, D. E. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0368-z · Cited by 22
Self-citationThe challenges of checkpoint inhibition in the treatment of multiple myeloma
Paul, B. A., Kang, S., Zheng, Z., & Kang, Y. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.10.003 · Cited by 22
Role of FcγRs in Antibody-Based Cancer Therapy
Graziano, R. F., & Engelhardt, J. (2019) · Current topics in microbiology and immunology · doi:10.1007/82_2019_150 · Cited by 23
Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
Hosen, N. (2019) · Cancers · doi:10.3390/cancers11122024 · Cited by 23
Antibody-drug conjugates for multiple myeloma
McMillan, A., Warcel, D., & Popat, R. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1802422 · Cited by 22
Anti-Angiogenic Activity of Drugs in Multiple Myeloma
Saltarella, I., Altamura, C., Campanale, C., Laghetti, P., Vacca, A., Frassanito, M. A., & Desaphy, J. (2023) · Cancers · doi:10.3390/cancers15071990 · Cited by 21
Metadata
- Authors
- Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., Belch, A., Reece, D., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R. Z., Taniwaki, M., Röllig, C., Einsele, H., Wu, K. L., Singhal, A., San-Miguel, J., Matsumoto, M., Katz, J., Bleickardt, E., Poulart, V., Anderson, K. C., & Richardson, P.
- Affiliations
- Dalhousie University (CA)
- National and Kapodistrian University of Athens (GR)
- Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
- Medical University of Silesia (PL)
- Centre Hospitalier Universitaire de Nantes (FR)
- Tel Aviv University (IL)
- University of Alberta (CA)
- Princess Margaret Cancer Centre (CA)
- Alfred Health (AU)
- Barts Health NHS Trust (GB)
- The University of Texas MD Anderson Cancer Center (US)
- Kyoto Prefectural University of Medicine (JP)
- Technische Universität Dresden (DE)
- Universitätsklinikum Würzburg (DE)
- Ziekenhuisnetwerk Antwerpen Stuivenberg (BE)
- AbbVie Biotherapeutics (United States) (US)
- National Hospital Organization (JP)
- Bristol-Myers Squibb (United States) (US)
- Dana-Farber Cancer Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-08-13
- Volume
- 373
- Issue
- 7
- Pages
- 621-631
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2201190784
- Semantic Scholar
- fb9d8d9019089b66fbe8ecd85963014c537e649e
- Cited by
- 1,322
- References
- 15
- Citations by year
- 2026: 29 · 2025: 60 · 2024: 63 · 2023: 87 · 2022: 95 · 2021: 147 · 2020: 174 · 2019: 132 · 2018: 154 · 2017: 187 · 2016: 160 · 2015: 33
- FWCI
- 139.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb
- AbbVie Biotherapeutics
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- elotuzumab, relapsed/refractory multiple myeloma, SLAMF7, lenalidomide, dexamethasone, progression-free survival, overall response rate, monoclonal antibodies, combination therapy, adverse events, lymphopenia, neutropenia, infusion reactions, interim analysis, overall survival
- MeSH terms
- Signaling Lymphocytic Activation Molecule Family, Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Middle Aged, Multiple Myeloma, Receptors, Immunologic, Recurrence, Thalidomide, Disease-Free Survival, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
